Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control

Novo Nordisk A/S2,745 enrolled

Overview

This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood glucose control in type 2 diabetes.

Study Type

OBSERVATIONAL

Enrollment

2,745

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level * Patient agreeing to take part in the study and capable of completing a self-questionnaire. Exclusion Criteria: * Hypersensitivity to insulin or to one of the excipients * Treatment with insulin for at least 6 months * Participant in a clinical trial for diabetes on entry into the observational study

Locations (1)

Novo Nordisk Investigational Site

Paris La Défense, France

Outcomes

Primary Outcomes

HbA1c

Time frame: After 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.